SEARCH

SEARCH BY CITATION

References

  • 1
    Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 15560.
  • 2
    Hill SL, Berry RE. Subclavian vein thrombosis: a continuing challenge. Surgery 1990; 108: 19.
  • 3
    Kommareddy A, Zaroukian MH, Hassouna HI. Upper extremity deep venous thrombosis. Semin Thromb Hemost 2002; 28: 8999.
  • 4
    Burihan E, de Figueiredo LF, Francisco JJ, Miranda JF. Upper-extremity deep venous thrombosis: analysis of 52 cases. Cardiovasc Surg 1993; 1: 1922.
  • 5
    Otten TR, Stein PD, Patel KC, Mustafa S, Silbergleit A. Thromboembolic disease involving the superior vena cava and brachiocephalic veins. Chest 2003; 123: 80912.
  • 6
    Prandoni P, Bernardi E, Marchiori A, Lensing AW, Prins MH, Villalta S, Bagatella P, Sartor D, Piccioli A, Simioni P, Pagnan A, Girolami A. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. BMJ 2004; 329: 4845.
  • 7
    Horattas MC, Wright DJ, Fenton AH, Evans DM, Oddi MA, Kamienski RW, Shields EF. Changing concepts of deep venous thrombosis of the upper extremity–report of a series and review of the literature. Surgery 1988; 104: 5617.
  • 8
    Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Mannucci PM. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 2004; 110: 56670.
  • 9
    Leebeek FW, Stadhouders NA, van Stein D, Gomez-Garcia EB, Kappers-Klunne MC. Hypercoagulability states in upper-extremity deep venous thrombosis. Am J Hematol 2001; 67: 1519.
  • 10
    Prandoni P, Polistena P, Bernardi E, Cogo A, Casara D, Verlato F, Angelini F, Simioni P, Signorini GP, Benedetti L, Girolami A. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997; 157: 5762.
  • 11
    Heron E, Lozinguez O, Alhenc-Gelas M, Emmerich J, Fiessinger JN. Hypercoagulable states in primary upper-extremity deep vein thrombosis. Arch Intern Med 2000; 160: 3826.
  • 12
    Martinelli I, Cattaneo M, Panzeri D, Taioli E, Mannucci PM. Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med 1997; 126: 70711.
  • 13
    Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 116773.
  • 14
    Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 71522.
  • 15
    Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 2513.
  • 16
    Baarslag HJ, Koopman MM, Hutten BA, Linthorst Homan MW, Büller HR, Reekers JA, van Beek EJ. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med 2004; 15: 5037.
  • 17
    Vaya A, Mira Y, Mateo J, Falco C, Villa P, Estelles A, Corella D, Fontcuberta J, Aznar J. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003; 89: 4527.
  • 18
    Teruya T, Arfvidsson B, Eklof B. Could prolonged air travel be casually associated with subclavian vein thrombosis. J Travel Med 2002; 9: 1719.
  • 19
    Mandala M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, Ventura A, Peruzzotti G, Severi G, Pelicci PG, Biffi R, Orsi F, Cinieri S, Goldhirsch A. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004; 15: 5903.
  • 20
    Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 14537.
  • 21
    Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 157380.
  • 22
    Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM, Lowe GD. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116: 8514.
  • 23
    Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, van der Meer FJ, Huisman MV. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004; 89: 2016.
  • 24
    Van Rooden CJ, Tesselaar ME, Osanto S, Rosendaal FR, Huisman MV. Deep vein thrombosis associated with central venous catheters - a review. J Thromb Haemost 2005; 3: 240919.
  • 25
    Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices–prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 2513.
  • 26
    Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112: 4238.
  • 27
    Abdelkefi A, Ben Othman T, Kammoun L, Chelli M, Romdhane NB, Kriaa A, Ladeb S, Torjman L, Lakhal A, Achour W, Ben Hassen A, Hsairi M, Ladeb F, Ben Abdeladhim A. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. Thromb Haemost 2004; 92: 65461.
  • 28
    Reichardt P, Kretzsxchmar A, Biakhov M. A phase III randomized, double blind, placebo- controlled study evaluating the efficacy and safety of daily low-molecular-weight-heparin (dalteparin sodium, fragmin) in preventing catheter-related complications (CRCs) in cancer patients with central catheters (CVCs). Proc Am Soc Clin Oncol 2002; 21: 369 (abstract).
  • 29
    Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, McCleod D, Burton E, Andreou P, Anderson D. A randomized double-blind placebo-controlled study of low dise warfarin for the prevention of symptomatic cantral venous catheter-associated thrombosis in patients with cancer. Blood 2002; 100: 703a (abstract).
  • 30
    Vardy JL, Engelhardt K, Cox K. Subcutaneous central venous access port devices (CV APDs) inserted by interventional radiologists in cancer patients. Proc Am Soc Clin Oncol 2002; 21: 2568 (abstract).